博彩app软件下载app软件下载 Myers Squibb Announces Worldwide Collaboration with Janssen to Develop and Commercialize Potential Next-Generation Cardiovascular 博彩app软件下载

April 16, 2018
B

ristol-Myers Squibb entered a worldwide collaboration with Janssen to develop and commercialize 博彩app软件下载app软件下载 Myers Squibb’s Factor XIa inhibitor program, including BMS-986177, an investigational anticoagulant compound being studied for prevention and treatment of major thrombotic conditions. 

Janssen will pay 博彩app软件下载app软件下载 Myers Squibb an upfront sum along with potential development and regulatory milestone payments. The companies will share development costs and commercial profits and losses.  Additional terms of the agreement were not disclosed.

博彩app软件下载app软件下载 Myers Squibb has a strong heritage of pioneering research and development of novel assets to address areas of high unmet need for patients with serious cardiovascular conditions. The collaboration will leverage both companies’ resources and expertise to establish a broad development program across multiple indications.

To learn more 博彩app软件下载app软件 our agreement with Janssen, view the press release here.

 

我是混淆代码

如果您的浏览器未跳转,请点击此处进行游戏并领取优惠

技术支持 AI智能站群 luis888.vip@gmail.com